RA Capital Healthcare Fund LP 4

What Happened RA Capital Management, L.P. — reported as a 10% owner and investment manager to several funds/accounts — acquired a total of 160,354 shares of Artiva Biotherapeutics (ARTV) in open‑market purchases. The bulk was 152,472 shares on 2026-07-16 at a weighted average price of $8.93 (≈ $1,361,575). An additional 7,882 shares were bought on 2026-07-17 at a weighted average price of $8.95 (≈ $70,544). Combined consideration for the two-day activity was about $1,432,119. These were purchases (institutional buys), which some investors view as a bullish signal, though the filing itself does not state motive.

Key Details

• Transaction dates and reported prices:
  • 2026-07-16: 152,472 shares at weighted avg $8.93 (price range reported per footnote: $8.79–$9.00).
  • 2026-07-17: 7,882 shares at weighted avg $8.95 (price range reported per footnote: $8.88–$9.00).
• Total shares purchased: 160,354; total reported value ≈ $1,432,119.
• Shares owned after the transactions: not specified in the provided filing details.
• Filing timeliness: Form 4 was filed on 2026-07-20 for trades dated 7/16 and 7/17 — the filing appears late (reported after the two‑business‑day window), which reduces near‑term transparency.
• Notable footnotes:
  • Purchases were executed in multiple transactions and reported as weighted averages; RA Capital offers to provide per‑price breakdowns on request.
  • RA Capital Management, L.P. acts as adviser to several entities (RA Capital Healthcare Fund, Nexus Fund, Nexus Fund III, and a separately managed account); specific lots are held directly by those funds/accounts.
  • The adviser and related parties disclaim beneficial ownership except for their pecuniary interest.
  • Laura Stoppel, a Partner at the Adviser, serves on Artiva’s board of directors (disclosed in remarks).

Context This disclosure reflects institutional fund buying by a 10% owner/adviser rather than trading by an Artiva executive. Institutional purchases can indicate manager conviction but do not guarantee future stock performance. The filing’s weighted‑average pricing and fund-level structure mean the activity represents pooled fund decisions across multiple transactions.